Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients

The introduction and success of imatinib mesylate (IM) has become a paradigm shift in chronic myeloid leukemia (CML) treatment. However, the high efficacy of IM has been hampered by the issue of clinical resistance that might due to pharmacogenetic variability. In the current study, the contribution of three common single nucleotide polymorphisms (SNPs) of ABCB1 (T1236C, G2677T/A and C3435T) and two SNPs of ABCG2 (G34A and C421A) genes in mediating resistance and/or good response among 215 CML patients on IM therapy were investigated. Among these patients, the frequency distribution of ABCG2 421 CC, CA and AA genotypes were significantly different between IM good response and resistant groups (P = 0.01). Resistance was significantly associated with patients who had homozygous ABCB1 1236 CC genotype with OR 2.79 (95%CI: 1.217-6.374, P = 0.01). For ABCB1 G2677T/A polymorphism, a better complete cytogenetic remission was observed for patients with variant TT/AT/AA genotype, compared to other genotype groups (OR = 0.48, 95%CI: 0.239-0.957, P = 0.03). Haplotype analysis revealed that ABCB1 haplotypes (C(1236)G(2677)C(3435)) was statistically linked to higher risk to IM resistance (25.8% vs. 17.4%, P = 0.04), while ABCG2 diplotype A(34)A(421) was significantly correlated with IM good response (9.1% vs. 3.9%, P = 0.03). In addition, genotypic variant in ABCG2 421C>A was associated with a major molecular response (MMR) (OR = 2.20, 95%CI: 1.273-3.811, P = 0.004), whereas ABCB1 2677G>T/A variant was associated with a significantly lower molecular response (OR = 0.49, 95%CI: 0.248-0.974, P = 0.04). However, there was no significant correlation of these SNPs with IM intolerance and IM induced hepatotoxicity. Our results suggest the usefulness of genotyping of these single nucleotide polymorphisms in predicting IM response among CML patients. (C) 2014 Elsevier Masson SAS. All rights reserved.